Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765928 | 0.93 | KMT2A (0.55) | ALDH1A1KMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6766441 | 0.90 | ALDH1A1 (0.53) | ALDH1A1KMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6768724 | 0.90 | ALDH1A1 (0.54) | ALDH1A1KMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6768950 | 0.87 | KMT2A (0.52) | ALDH1A1KMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6768688 | 0.87 | KMT2A (0.53) | ALDH1A1KMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6765995 | 0.87 | MEN1 (0.62) | ALDH1A1KMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6770107 | 0.86 | MEN1 (0.51) | ALDH1A1KMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6769248 | 0.86 | MEN1 (0.51) | ALDH1A1KMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6768765 | 0.86 | ALDH1A1 (0.57) | ALDH1A1KMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6770955 | 0.85 | MEN1 (0.54) | ALDH1A1KMT2ALMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677336-B2 | PARTIAL FATTY ACID OXIDATION INHIBITORS; PROTECT SKELETAL MUSCLES AGAINST DAMAGE RESULTING FROM TRAUMA OR SYSTEMIC DISEASES, TREAT SHOCK CONDITIONS, PRESERVE DONOR TISSUE AND ORGANS USED IN TRANSPLANTS | CV THERAPEUTICS, INC. | 2004-01-13 | — | — | US | claimed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | claimed |
| US-20020016463-A1 | Substituted piperazine compounds | CV THERAPEUTICS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | claimed |
| US-6677336-B2 | PARTIAL FATTY ACID OXIDATION INHIBITORS; PROTECT SKELETAL MUSCLES AGAINST DAMAGE RESULTING FROM TRAUMA OR SYSTEMIC DISEASES, TREAT SHOCK CONDITIONS, PRESERVE DONOR TISSUE AND ORGANS USED IN TRANSPLANTS | CV THERAPEUTICS, INC. | 2004-01-13 | — | — | US | disclosed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020016463-A1 | Substituted piperazine compounds | CV THERAPEUTICS, INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016463-A1 | Substituted piperazine compounds | ATP2A1, CPT1B, TNNC1 | ALDH1A1 35/4885KMT2A 4291/4885LMNA 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.